Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma.
Naito S, Ichiyanagi O, Kato T, Kanno H, Narisawa T, Kurokawa M, Ushijima M, Ozawa M, Yagi M, Kurota Y, Fukuhara H, Yamagishi A, Sakurai T, Nishida H, Kawazoe H, Yamanobe T, Tsuchiya N. Naito S, et al. Among authors: ozawa m. Sci Rep. 2019 Oct 29;9(1):15451. doi: 10.1038/s41598-019-51305-7. Sci Rep. 2019. PMID: 31664053 Free PMC article.
Impact of eIF4E phosphorylation at Ser209 via MNK2a on tumour recurrence after curative surgery in localized clear cell renal cell carcinoma.
Ichiyanagi O, Ito H, Naito S, Kabasawa T, Kanno H, Narisawa T, Ushijima M, Kurota Y, Ozawa M, Sakurai T, Nishida H, Kato T, Yamakawa M, Tsuchiya N. Ichiyanagi O, et al. Among authors: ozawa m. Oncotarget. 2019 Jun 18;10(40):4053-4068. doi: 10.18632/oncotarget.27017. eCollection 2019 Jun 18. Oncotarget. 2019. PMID: 31258849 Free PMC article.
Risk of SOFA Deterioration in Conservative Treatment for Emphysematous Pyelonephritis: Pitfalls of Current Trends in Therapeutics from Multicenter Clinical Experience.
Ozawa M, Ichiyanagi O, Fujita S, Naito S, Fukuhara H, Suenaga S, Takai S, Narisawa T, Hosoya N, Ishii T, Yamanobe T, Muto A, Suzuki H, Nishida H, Kato T, Tsuchiya N. Ozawa M, et al. Curr Urol. 2019 May 10;12(3):134-141. doi: 10.1159/000489431. Curr Urol. 2019. PMID: 31316321 Free PMC article.
New prognostic model for synchronous metastatic renal cell carcinoma.
Naito S, Kato T, Ichiyanagi O, Narisawa T, Kurokawa M, Yagi M, Ushijima M, Ozawa M, Kanno H, Kurota Y, Fukuhara H, Kuboki Y, Yamagishi A, Sakurai T, Nishida H, Yamanobe T, Tsuchiya N. Naito S, et al. Among authors: ozawa m. Int J Urol. 2020 May;27(5):448-456. doi: 10.1111/iju.14215. Epub 2020 Mar 23. Int J Urol. 2020. PMID: 32207204
Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, Shinohara N; Japanese Urological Oncology Group. Osawa T, et al. Among authors: ozawa m. Cancer Sci. 2020 Jul;111(7):2460-2471. doi: 10.1111/cas.14449. Epub 2020 Jun 12. Cancer Sci. 2020. PMID: 32402135 Free PMC article.
Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma.
Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group. Nakai Y, et al. Among authors: ozawa m. J Geriatr Oncol. 2021 Jun;12(5):834-837. doi: 10.1016/j.jgo.2020.12.012. Epub 2020 Dec 31. J Geriatr Oncol. 2021. PMID: 33388281 No abstract available.
External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.
Tamura K, Osawa T, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Sugimoto M, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Komiyama M, Tanaka K, Yokomizo A, Kohei N, Shinohara N, Miyake H; Japanese Urological Oncology Group. Tamura K, et al. Among authors: ozawa m. Jpn J Clin Oncol. 2021 Apr 30;51(5):810-818. doi: 10.1093/jjco/hyaa264. Jpn J Clin Oncol. 2021. PMID: 33479762
1,266 results